Tele-Stethoscope Inc.

Tele-Stethoscope Inc., a self-certified small disadvantaged business based in Louisville, Kentucky, develops mobile phone-based diagnostic algorithms for remote detection of chronic respiratory, cardiac, and pregnancy-related diseases as a prime recipient of federal research grants and as a prime contractor on federal R&D work. The vendor operates exclusively as a prime — all four awards in the source are prime positions — and competes on a full-and-open basis with no set-aside designations across its federal footprint.

The company's capability portfolio centers on physics-based acoustic data analysis and machine-learning algorithm development for Class 2 medical device software deployed on consumer smartphones. Work performed includes developing Phase I algorithms and demonstrating technical feasibility for mobile phone-based diagnostics that use auscultation recordings to predict spirometry and echocardiogram findings, with clinical recruitment of 237 patients previously referred to pulmonary function testing within a rural health system (National Heart, Lung, and Blood Institute Cardiovascular Diseases Research grant, CFDA 93.837, $406,367 awarded September 1, 2026, performance through August 31, 2027). The vendor also received a $338,196 firm fixed price contract from the HHS Office of the Assistant Secretary for Preparedness and Response (awarded September 15, 2023, completed September 14, 2024) for research and development of digital multi-channel monitors detecting respiratory diseases using mobile phones, and holds a second grant from NHLBI for algorithm development targeting preeclampsia and hypertension detection via patient self-recording ($406,367 awarded September 20, 2024, completed August 31, 2026) and a third NHLBI grant (awarded September 15, 2023, completed January 10, 2025) for early detection of COPD using the vendor's proprietary Tele-Stethoscope acoustic analysis technology. The technology employs chaos-based biofluid dynamics and passive hemodynamic measurement rather than neural networks, intended for use in telehealth, pre-office screening, and low-resource settings where gold-standard testing is unavailable.

Customer concentration is heavy with HHS: three awards are funded by NHLBI and one by ASPR, representing 100% of recent awards. Activity is sparse — two awards in 2023, one in 2024, one in 2026 — with combined potential value of $338 thousand but combined obligated dollars of $2.3 million (667% of potential value, indicating substantial prior-year carry-over obligations). One award reaches completion within the next twenty-four months, creating a single recompete opportunity.